BR0112646A - Pró-drogas de análogos de nucleotìdeo de fosfonato e métodos para selecionar e preparar as mesmas - Google Patents
Pró-drogas de análogos de nucleotìdeo de fosfonato e métodos para selecionar e preparar as mesmasInfo
- Publication number
- BR0112646A BR0112646A BR0112646-6A BR0112646A BR0112646A BR 0112646 A BR0112646 A BR 0112646A BR 0112646 A BR0112646 A BR 0112646A BR 0112646 A BR0112646 A BR 0112646A
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- selecting
- methods
- compounds
- nucleotide analog
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 229940002612 prodrug Drugs 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 title abstract 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000007858 starting material Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- -1 magnesium alkoxide Chemical class 0.000 abstract 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical class COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical class [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22002100P | 2000-07-21 | 2000-07-21 | |
US60/220,021 | 2000-07-21 | ||
PCT/US2001/023104 WO2002008241A2 (en) | 2000-07-21 | 2001-07-20 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0112646A true BR0112646A (pt) | 2003-06-24 |
BRPI0112646B1 BRPI0112646B1 (pt) | 2017-10-17 |
BRPI0112646B8 BRPI0112646B8 (pt) | 2021-05-25 |
Family
ID=22821718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0112646A BRPI0112646B8 (pt) | 2000-07-21 | 2001-07-20 | pró-fármacos de análogos de nucleotídeo de fosfonato e composições que as compreende |
Country Status (37)
Country | Link |
---|---|
US (10) | US20040018150A1 (pt) |
EP (3) | EP3235823A1 (pt) |
JP (4) | JP4651264B2 (pt) |
KR (2) | KR100767432B1 (pt) |
CN (2) | CN1291994C (pt) |
AP (1) | AP1466A (pt) |
AU (3) | AU8294101A (pt) |
BE (1) | BE2016C018I2 (pt) |
BG (1) | BG66037B1 (pt) |
BR (1) | BRPI0112646B8 (pt) |
CA (3) | CA2725819C (pt) |
CY (2) | CY2016008I1 (pt) |
CZ (2) | CZ304734B6 (pt) |
DK (2) | DK1301519T4 (pt) |
EA (1) | EA004926B1 (pt) |
EE (1) | EE05366B1 (pt) |
ES (2) | ES2536972T5 (pt) |
FR (1) | FR16C0013I2 (pt) |
HK (2) | HK1054238A1 (pt) |
HR (2) | HRP20160074B1 (pt) |
HU (2) | HU230960B1 (pt) |
IL (1) | IL153658A0 (pt) |
IS (1) | IS2985B (pt) |
LT (2) | LT2682397T (pt) |
LU (1) | LU93029I2 (pt) |
MX (1) | MXPA03000587A (pt) |
NL (1) | NL300803I2 (pt) |
NO (6) | NO336718B1 (pt) |
NZ (3) | NZ536942A (pt) |
OA (1) | OA12393A (pt) |
PL (1) | PL213214B1 (pt) |
PT (2) | PT1301519E (pt) |
SI (2) | SI2682397T1 (pt) |
TR (1) | TR200300055T2 (pt) |
UA (1) | UA75889C2 (pt) |
WO (1) | WO2002008241A2 (pt) |
ZA (1) | ZA200210271B (pt) |
Families Citing this family (219)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1301519E (pt) * | 2000-07-21 | 2015-06-11 | Gilead Sciences Inc | Profármacos de análogos de nucleótidos de fosfonato e métodos para selecionar e preparar os mesmos |
US7388002B2 (en) * | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
IL161901A0 (en) * | 2001-11-14 | 2005-11-20 | Biocryst Pharmaceuticals Inc A | Nucleosides, preparation thereof and use as inhibiDevice for the reading and the signalling of environmental parameters tors of rna viral polymerases |
US20040121316A1 (en) | 2002-04-26 | 2004-06-24 | Gilead Sciences, Inc. | Method and compositions for identifying anti-HIV therapeutic compounds |
US20050239054A1 (en) * | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
CA2485702C (en) | 2002-05-13 | 2011-07-19 | Metabasis Therapeutics, Inc. | Novel phosphonic acid based prodrugs of pmea and its analogues |
DK1583542T3 (da) * | 2003-01-14 | 2008-09-22 | Gilead Sciences Inc | Sammensætninger og fremgangsmåder til antiviral kombinationsterapi |
SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US7407965B2 (en) * | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US20090247488A1 (en) * | 2003-04-25 | 2009-10-01 | Carina Cannizzaro | Anti-inflammatory phosphonate compounds |
WO2004096285A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
US7470724B2 (en) * | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
US7432261B2 (en) * | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
EA200501676A1 (ru) | 2003-04-25 | 2006-04-28 | Джилид Сайэнс, Инк. | Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты) |
CN101410120A (zh) * | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | 抗炎的膦酸酯化合物 |
WO2004096287A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
WO2005044308A1 (en) * | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
US7427624B2 (en) | 2003-10-24 | 2008-09-23 | Gilead Sciences, Inc. | Purine nucleoside phosphorylase inhibitory phosphonate compounds |
JP2007508843A (ja) | 2003-10-24 | 2007-04-12 | ギリアード サイエンシーズ, インコーポレイテッド | 治療用化合物の同定のための方法および組成物 |
JP2007515495A (ja) | 2003-12-22 | 2007-06-14 | ギリアード サイエンシーズ, インコーポレイテッド | 4’−置換カルボビル誘導体およびアバカビル誘導体ならびにhivおよびhcv抗ウイルス活性を有する関連化合物 |
US20050153990A1 (en) * | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
US20070281907A1 (en) * | 2003-12-22 | 2007-12-06 | Watkins William J | Kinase Inhibitor Phosphonate Conjugates |
SG149075A1 (en) * | 2003-12-30 | 2009-01-29 | Gilead Sciences Inc | Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases |
NZ548532A (en) * | 2004-01-21 | 2009-09-25 | Gilead Sciences Inc | Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis |
US8416242B1 (en) | 2004-05-14 | 2013-04-09 | Nvidia Corporation | Method and system for interpolating level-of-detail in graphics processors |
US8411105B1 (en) | 2004-05-14 | 2013-04-02 | Nvidia Corporation | Method and system for computing pixel parameters |
US7079156B1 (en) | 2004-05-14 | 2006-07-18 | Nvidia Corporation | Method and system for implementing multiple high precision and low precision interpolators for a graphics pipeline |
US8432394B1 (en) | 2004-05-14 | 2013-04-30 | Nvidia Corporation | Method and system for implementing clamped z value interpolation in a raster stage of a graphics pipeline |
AU2005254940A1 (en) | 2004-06-08 | 2005-12-29 | Metabasis Therapeutics, Inc. | Lewis acid mediated synthesis of cyclic esters |
PT2258376T (pt) * | 2004-07-27 | 2019-05-31 | Gilead Sciences Inc | Análogos fosfonatados de compostos inibidores do vih |
EP2842559A3 (en) * | 2005-04-08 | 2015-03-18 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
WO2006110655A2 (en) | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
CN100359315C (zh) * | 2005-05-26 | 2008-01-02 | 林维宣 | 兽药残留能力验证样品及制备方法 |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
CN100396689C (zh) * | 2006-03-07 | 2008-06-25 | 中国医学科学院医药生物技术研究所 | 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物 |
PT2020996E (pt) | 2006-05-16 | 2012-02-20 | Gilead Sciences Inc | Método e composições para tratar neoplasias malignas hematológicas |
WO2008007392A2 (en) | 2006-07-12 | 2008-01-17 | Matrix Laboratories Limited | Process for the preparation of tenofovir |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
AU2008302676B2 (en) * | 2007-06-26 | 2013-02-28 | University Of Wyoming Research Corporation D/B/A Western Research Institute | Treatment and prevention systems for acid mine drainage and halogenated contaminants |
US8441497B1 (en) * | 2007-08-07 | 2013-05-14 | Nvidia Corporation | Interpolation of vertex attributes in a graphics processor |
CA2713105C (en) * | 2008-01-25 | 2016-06-07 | Chimerix, Inc. | Methods of treating viral infections |
TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
NZ588796A (en) | 2008-04-25 | 2012-07-27 | Cipla Ltd | Crystalline form of tenofovir disoproxil and a process for its preparation |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
CA2729168A1 (en) * | 2008-07-02 | 2010-02-04 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
CN102089318B (zh) * | 2008-07-08 | 2014-05-21 | 吉里德科学公司 | Hiv抑制剂化合物的盐 |
EA019341B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Фосфорамидаты нуклеозидов |
PA8855701A1 (es) | 2008-12-23 | 2010-07-27 | Análogos de nucleósidos | |
WO2010075554A1 (en) * | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Synthesis of purine nucleosides |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
US10023600B2 (en) | 2009-09-21 | 2018-07-17 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs |
ES2629165T3 (es) | 2010-02-12 | 2017-08-07 | Chimerix, Inc. | Métodos de tratamiento de una infección vírica |
PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
BR112012024884A2 (pt) | 2010-03-31 | 2016-10-18 | Gilead Pharmasset Llc | síntese estereosseletiva de ativos contendo fósforo |
CA2795054A1 (en) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
EP2563367A4 (en) | 2010-04-26 | 2013-12-04 | Chimerix Inc | METHODS OF TREATING RETROVIRAL INFECTIONS AND ASSOCIATED DOSAGE REGIMES |
CN103052646A (zh) | 2010-07-19 | 2013-04-17 | 吉里德科学公司 | 用于制备非对映异构体纯氨基磷酸酯前药的方法 |
AP3269A (en) | 2010-07-22 | 2015-05-31 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridaevirus infections |
EP2646453A1 (en) | 2010-11-30 | 2013-10-09 | Gilead Pharmasset LLC | Compounds |
CA2819548C (en) | 2010-12-10 | 2019-04-09 | Sigmapharm Laboratories, Llc | Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs |
ZA201103820B (en) | 2010-12-13 | 2012-01-25 | Laurus Labs Private Ltd | Process for the preparation of tenofovir |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US9550803B2 (en) | 2011-05-06 | 2017-01-24 | University Of Southern California | Method to improve antiviral activity of nucleotide analogue drugs |
EP3199537B1 (en) | 2011-05-19 | 2018-10-17 | Gilead Sciences, Inc. | Processes and intermediates for preparing anti-hiv agents |
CN103732594A (zh) | 2011-08-16 | 2014-04-16 | 吉联亚科学公司 | 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐 |
AU2014271320B2 (en) * | 2011-08-16 | 2017-02-23 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
CN104244945B (zh) | 2011-09-16 | 2016-08-31 | 吉利德制药有限责任公司 | 用于治疗hcv的方法 |
AU2014215976B2 (en) * | 2011-10-07 | 2016-06-30 | Gilead Sciences, Inc. | Methods for preparing anti-viral nucleotide analogs |
AU2016228317B2 (en) * | 2011-10-07 | 2018-07-19 | Gilead Sciences, Inc. | Methods for preparing anti-viral nucleotide analogs |
CN103842366B (zh) | 2011-10-07 | 2017-06-16 | 吉利德科学公司 | 制备抗病毒核苷酸类似物的方法 |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
EP3578563B1 (en) | 2011-12-22 | 2021-04-14 | Geron Corporation | Guanine analogs as telomerase substrates and telomere length affectors |
CA2863662A1 (en) * | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
AU2012327170A1 (en) | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
CN107312039B (zh) * | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
GB201215696D0 (en) * | 2012-09-03 | 2012-10-17 | Ithemba Pharmaceuticals Pty Ltd | A process for the preparation of (R)-9-[2-(Phosphonometh-Oxy)propyl]adenine (PMPA) |
AU2013340559B2 (en) * | 2012-10-29 | 2018-03-15 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
CN102899327B (zh) * | 2012-11-06 | 2014-06-11 | 清华大学深圳研究生院 | 一种抗病毒的小核酸及其温度敏感型凝胶制剂与应用 |
US9730940B2 (en) * | 2012-11-16 | 2017-08-15 | Merck Sharp & Dohme | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
CN103848868B (zh) * | 2012-12-04 | 2017-04-12 | 蚌埠丰原涂山制药有限公司 | 制备替诺福韦的方法 |
CN103848869B (zh) * | 2012-12-04 | 2016-12-21 | 上海医药工业研究院 | 制备替诺福韦的方法 |
SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
CN104072539B (zh) * | 2013-03-25 | 2017-03-29 | 安徽贝克联合制药有限公司 | 替诺福韦双(4‑乙酰氨基苯酚氧基)酯及其制备方法和其应用 |
JP6262848B2 (ja) * | 2013-05-21 | 2018-01-17 | 成都先導薬物開発有限公司 | 薬物標的の捕獲方法 |
ZA201404147B (en) | 2013-06-07 | 2016-01-27 | Cipla Ltd | An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl] methoxy]propyl]adenine |
PT3650014T (pt) | 2013-08-27 | 2021-12-27 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
WO2015040640A2 (en) * | 2013-09-20 | 2015-03-26 | Laurus Labs Private Limited | An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof |
EP2860185A1 (en) | 2013-10-09 | 2015-04-15 | Zentiva, k.s. | An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof |
WO2015079455A2 (en) * | 2013-11-27 | 2015-06-04 | Laurus Labs Private Limited | A recycling process for preparing tenofovir alafenamide diastereomers |
IN2014MU00118A (pt) | 2014-01-14 | 2015-08-28 | Mylan Lab Ltd | |
TWI660965B (zh) * | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
CN104804042B (zh) * | 2014-01-24 | 2018-01-19 | 齐鲁制药有限公司 | 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途 |
WO2015120057A1 (en) | 2014-02-05 | 2015-08-13 | Gilead Sciences, Inc. | Pharmaceutical combinations against co-infection with hiv and tuberculosis |
CN106061984A (zh) | 2014-02-13 | 2016-10-26 | 配体药物公司 | 前药化合物及其用途 |
WO2015127848A1 (zh) * | 2014-02-27 | 2015-09-03 | 四川海思科制药有限公司 | 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用 |
CN105001262B (zh) * | 2014-04-18 | 2017-09-01 | 四川海思科制药有限公司 | 芳基取代的磷酰胺类衍生物及其在医学上的应用 |
WO2015161785A1 (zh) * | 2014-04-21 | 2015-10-29 | 四川海思科制药有限公司 | 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法 |
CN105085571A (zh) * | 2014-05-20 | 2015-11-25 | 四川海思科制药有限公司 | 替诺福韦艾拉酚胺复合物及其制备方法和用途 |
WO2015197006A1 (zh) * | 2014-06-25 | 2015-12-30 | 四川海思科制药有限公司 | 一种取代的氨基酸硫酯类化合物、其组合物及应用 |
EP3164136A4 (en) | 2014-07-02 | 2018-04-04 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
CN106687467A (zh) * | 2014-09-30 | 2017-05-17 | 韩美精密化学株式会社 | 高纯度(r)‑9‑[2‑(磷酰甲氧基)丙基]腺嘌呤的制备方法 |
KR101703257B1 (ko) | 2014-09-30 | 2017-02-06 | 한미정밀화학주식회사 | 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법 |
KR101703258B1 (ko) | 2014-12-30 | 2017-02-06 | 한미정밀화학주식회사 | 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법 |
EP3203995A4 (en) | 2014-10-09 | 2019-05-15 | Board of Regents of the University of Nebraska | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS |
TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
CN108191913A (zh) * | 2014-11-12 | 2018-06-22 | 四川海思科制药有限公司 | 一种替诺福韦艾拉酚胺晶型a及其制备方法 |
CN104558036A (zh) * | 2014-12-11 | 2015-04-29 | 杭州和泽医药科技有限公司 | 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法 |
JP2018502118A (ja) | 2015-01-03 | 2018-01-25 | マイラン・ラボラトリーズ・リミテッドMylan Laboratories Limited | 非晶質ヘミフマル酸テノホビルアラフェナミドおよびその予備混合物を調製するプロセス |
WO2016187160A1 (en) * | 2015-05-16 | 2016-11-24 | Godx, Inc. | Point of need testing device and methods of use thereof |
CN106188139B (zh) * | 2015-05-29 | 2020-02-18 | 江苏天士力帝益药业有限公司 | 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用 |
CZ2015384A3 (cs) | 2015-06-05 | 2016-12-14 | Zentiva, K.S. | Pevné formy Tenofovir alafenamidu |
CA2987085A1 (en) * | 2015-06-17 | 2016-12-22 | Gilead Sciences, Inc. | Co-crystals, salts and solid forms of tenofovir alafenamide |
ES2945345T3 (es) | 2015-06-30 | 2023-06-30 | Gilead Sciences Inc | Formulaciones farmacéuticas |
CN107849071B (zh) | 2015-08-10 | 2021-03-09 | 默沙东公司 | 抗病毒的β氨基酸酯膦酰二胺化合物 |
TWI620754B (zh) * | 2015-08-26 | 2018-04-11 | Method for preparing amino phosphate derivative and preparation method thereof | |
TWI616452B (zh) * | 2015-08-26 | 2018-03-01 | Preparation method of nucleoside analog and intermediate thereof | |
TWI616453B (zh) * | 2015-08-27 | 2018-03-01 | Substituted amino acid thioester compounds, compositions and uses thereof | |
WO2017037608A1 (en) * | 2015-08-28 | 2017-03-09 | Laurus Labs Private Limited | Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof |
PT3349758T (pt) | 2015-09-16 | 2022-07-13 | Gilead Sciences Inc | Métodos para o tratamento de infeções pelo vírus arenaviridae |
PE20181207A1 (es) | 2015-11-09 | 2018-07-23 | Gilead Sciences Inc | Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana |
CN106800573B (zh) * | 2015-11-25 | 2020-03-10 | 四川海思科制药有限公司 | 一种核苷酸膦酸酯一水合物及其制备方法和在医药上的应用 |
EP3386512B1 (en) | 2015-12-10 | 2023-11-22 | Merck Sharp & Dohme LLC | Antiviral phosphodiamide prodrugs of tenofovir |
CN106866737B (zh) * | 2015-12-11 | 2020-11-20 | 南京圣和药物研发有限公司 | 膦酸衍生物及其应用 |
US10450335B2 (en) | 2015-12-15 | 2019-10-22 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
WO2017118928A1 (en) | 2016-01-06 | 2017-07-13 | Lupin Limited | Process for the separation of diastereomers of tenofovir alafenamide |
ES2806604T3 (es) | 2016-02-02 | 2021-02-18 | Sandoz Ag | Formas cristalinas de monofumarato de tenofovir alafenamida |
CN107709288A (zh) * | 2016-02-03 | 2018-02-16 | 四川海思科制药有限公司 | 一种磷酰胺衍生物及制备方法和用途 |
CN108350007B (zh) * | 2016-03-01 | 2020-04-10 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的腺嘌呤化合物及其药物组合物 |
CN107179355B (zh) * | 2016-03-11 | 2021-08-10 | 广东东阳光药业有限公司 | 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法 |
CZ2016156A3 (cs) | 2016-03-17 | 2017-09-27 | Zentiva, K.S. | Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí |
CN107226826A (zh) * | 2016-03-25 | 2017-10-03 | 江苏奥赛康药业股份有限公司 | 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物 |
WO2017211325A1 (zh) | 2016-06-05 | 2017-12-14 | 上海诚妙医药科技有限公司 | 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途 |
CN107698621A (zh) * | 2016-06-20 | 2018-02-16 | 杭州和泽医药科技有限公司 | 一种腺嘌呤衍生物的膦酸酯前药及其在医药上的应用 |
WO2017221189A1 (en) * | 2016-06-22 | 2017-12-28 | Laurus Labs Limited | An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof |
FI3597646T3 (fi) | 2016-08-19 | 2023-09-07 | Gilead Sciences Inc | Hi-virusinfektion profylaktiseen tai terapeuttiseen hoitoon käyttökelpoisia terapeuttisia yhdisteitä |
CN106317116A (zh) * | 2016-08-19 | 2017-01-11 | 张红利 | 磷酰胺核苷类化合物及其药学上可接受的盐与应用、药物组合物 |
US10449208B2 (en) | 2016-08-25 | 2019-10-22 | Merck Sharp & Dohme Corp. | Antiviral prodrugs of tenofovir |
CN106380484A (zh) * | 2016-08-29 | 2017-02-08 | 杭州百诚医药科技股份有限公司 | 一种替诺福韦艾拉酚胺的新晶型及其制备方法 |
WO2018042331A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
US10736908B2 (en) | 2016-10-26 | 2020-08-11 | Merck Sharp & Dohme Corp. | Antiviral aryl-amide phosphodiamide compounds |
CN106565785B (zh) * | 2016-11-09 | 2019-11-12 | 周雨恬 | 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途 |
CN108129514A (zh) * | 2016-12-01 | 2018-06-08 | 北京美倍他药物研究有限公司 | 磷酸/膦酸衍生物的单一异构体及其医药用途 |
TW201829412A (zh) | 2016-12-22 | 2018-08-16 | 美商默沙東藥廠 | 抗病毒之替諾福韋(tenofovir)之脂系酯前藥 |
CN110035760A (zh) | 2016-12-22 | 2019-07-19 | 默沙东公司 | 抗病毒苯甲基胺磷酰二胺化合物 |
WO2018115046A1 (en) | 2016-12-23 | 2018-06-28 | Sandoz Ag | Crystalline solid forms of tenofovir alafenamide |
TW202402300A (zh) | 2017-01-31 | 2024-01-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
WO2018153977A1 (en) | 2017-02-24 | 2018-08-30 | Hexal Ag | Stable composition of tenofovir alafenamide |
US20190374557A1 (en) * | 2017-02-28 | 2019-12-12 | Alexandre Vasilievich Ivachtchenko | Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof |
RU2659388C1 (ru) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
CN106866739B (zh) * | 2017-03-10 | 2018-11-02 | 华东师范大学 | 一种(r)-1-(6-氨基-9h-嘌呤-9-基)2-苯酯的制备方法 |
CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
CA3054822A1 (en) | 2017-03-20 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv post-exposure prophylaxis |
CN108794530A (zh) * | 2017-04-26 | 2018-11-13 | 上海医药工业研究院 | 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途 |
WO2018204198A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
KR102379965B1 (ko) * | 2017-05-19 | 2022-03-29 | 주식회사 종근당 | 테노포비르의 효율적인 제조방법 |
CN107266499B (zh) * | 2017-06-05 | 2019-07-02 | 珠海优润医药科技有限公司 | 一种抗病毒化合物及其制备方法 |
US20200113919A1 (en) | 2017-06-30 | 2020-04-16 | Cipla Limited | Pharmaceutical Compositions |
CN117982682A (zh) | 2017-07-11 | 2024-05-07 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
WO2019021319A1 (en) | 2017-07-27 | 2019-01-31 | Cipla Limited | PHARMACEUTICAL COMPOSITIONS |
ES2969496T3 (es) | 2017-08-01 | 2024-05-20 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
CN107655987B (zh) * | 2017-09-08 | 2020-11-03 | 厦门蔚扬药业有限公司 | 一种替诺福韦艾拉酚胺及其异构体的hplc检测方法 |
CN107522743A (zh) * | 2017-09-30 | 2017-12-29 | 深圳科兴生物工程有限公司 | 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法 |
WO2019084020A1 (en) | 2017-10-24 | 2019-05-02 | Gilead Sciences, Inc. | METHODS OF TREATING PATIENTS CO-INFECTED BY A VIRUS AND TUBERCULOSIS |
CN109942632B (zh) * | 2017-12-20 | 2021-08-31 | 上海博志研新药物研究有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
CN109942633B (zh) * | 2017-12-20 | 2021-08-31 | 上海新礼泰药业有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
US20200407382A1 (en) | 2017-12-30 | 2020-12-31 | Cipla Limited | Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof |
CA3087932A1 (en) | 2018-01-09 | 2019-07-18 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
KR20200108330A (ko) * | 2018-01-10 | 2020-09-17 | 누코리온 파마슈티컬스, 인코포레이티드. | 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물 |
EP3737359A4 (en) * | 2018-01-12 | 2021-11-03 | Board of Regents of the University of Nebraska | ANTIVIRAL PRODRUGS AND THEIR FORMULATIONS |
CA3089590C (en) | 2018-02-15 | 2022-12-06 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
PL3752496T3 (pl) | 2018-02-16 | 2023-11-27 | Gilead Sciences, Inc. | Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae |
CN108101943B (zh) * | 2018-02-28 | 2020-11-24 | 顾世海 | 一种替诺福韦前药或可药用盐及其在医药上的应用 |
US11458136B2 (en) | 2018-04-09 | 2022-10-04 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
CN112423750A (zh) | 2018-07-16 | 2021-02-26 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
US11826375B2 (en) | 2018-07-19 | 2023-11-28 | Merck Sharp & Dohme Llc | Phosphinic amide prodrugs of tenofovir |
KR20210060573A (ko) | 2018-09-19 | 2021-05-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 예방용 인테그라제 억제제 |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
CA3146263A1 (en) | 2019-07-19 | 2021-01-28 | Jose Gerardo Garcia Lerma | Hiv pre-exposure prophylaxis |
US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
JP2022546310A (ja) * | 2019-08-22 | 2022-11-04 | エモリー ユニバーシティー | ヌクレオシドプロドラッグ及びそれに関する使用 |
US20220372171A1 (en) * | 2019-09-20 | 2022-11-24 | Abbott Rapid Diagnostics International Unlimited Company | Antibody directed against tenofovir and derivatives thereof |
US11807625B2 (en) | 2019-11-26 | 2023-11-07 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ, インコーポレイテッド | SARS CoV-2感染を治療するための方法 |
EP4085062A1 (en) | 2020-02-20 | 2022-11-09 | Cipla Limited | Novel salts and/or co-crystals of tenofovir alafenamide |
CA3169340A1 (en) | 2020-03-12 | 2021-09-16 | Pavel R. Badalov | Methods of preparing 1'-cyano nucleosides |
CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司(Us) | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
WO2021202669A2 (en) | 2020-04-01 | 2021-10-07 | Reyoung Corporation | Nucleoside and nucleotide conjugate compounds and uses thereof |
AU2021251689B2 (en) | 2020-04-06 | 2024-06-13 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
KR20210125298A (ko) | 2020-04-08 | 2021-10-18 | 주식회사 파마코스텍 | 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법 |
WO2021216427A1 (en) | 2020-04-21 | 2021-10-28 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds |
JP2023528810A (ja) | 2020-05-29 | 2023-07-06 | ギリアード サイエンシーズ, インコーポレイテッド | レムデシビル治療方法 |
JP2023531524A (ja) | 2020-06-24 | 2023-07-24 | ギリアード サイエンシーズ, インコーポレイテッド | 1’-シアノヌクレオシド類似体及びその使用 |
US11680064B2 (en) | 2020-06-25 | 2023-06-20 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
CN113970612B (zh) * | 2020-07-22 | 2023-08-01 | 北京四环制药有限公司 | 一种高效液相色谱法测定丙酚替诺福韦有关物质的方法 |
DK4204421T3 (da) | 2020-08-27 | 2024-05-27 | Gilead Sciences Inc | Forbindelser og fremgangsmåder til behandling af virale infektioner |
CN112336695B (zh) * | 2020-09-28 | 2023-01-03 | 华北制药华坤河北生物技术有限公司 | 一种富马酸丙酚替诺福韦片剂及其制备方法和有关物质的检测方法 |
AU2021377614A1 (en) | 2020-11-11 | 2023-06-22 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
US11667656B2 (en) | 2021-01-27 | 2023-06-06 | Apotex Inc. | Crystalline forms of Tenofovir alafenamide |
CN113214322B (zh) * | 2021-04-30 | 2022-10-25 | 山东立新制药有限公司 | 替诺福韦绿色环保的制备方法 |
WO2022251594A1 (en) * | 2021-05-27 | 2022-12-01 | Antios Therapeutics, Inc. | Pharmacokinetics and dose-related improvments in subjects treated with phosphoramidate clevudine prodrugs |
WO2023102529A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
AU2022401696A1 (en) | 2021-12-03 | 2024-05-09 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
CN114369120A (zh) * | 2022-01-28 | 2022-04-19 | 石家庄龙泽制药股份有限公司 | 一种丙酚替诺福韦关键中间体的制备方法 |
US20230295172A1 (en) | 2022-03-02 | 2023-09-21 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS233665B1 (en) | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
CS263951B1 (en) | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
CS263952B1 (en) | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
CS264222B1 (en) | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
US5650510A (en) | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
US5057301A (en) | 1988-04-06 | 1991-10-15 | Neorx Corporation | Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents |
US5053215A (en) * | 1988-05-26 | 1991-10-01 | University Of Florida | NMR-assayable ligand-labelled trifluorothymidine containing composition and method for diagnosis of HSV infection |
US5744600A (en) | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
US5688778A (en) | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
JP2648516B2 (ja) | 1989-07-27 | 1997-09-03 | ダイセル化学工業株式会社 | 立体異性体の分離法 |
US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
JP2925753B2 (ja) | 1990-02-23 | 1999-07-28 | ダイセル化学工業株式会社 | 光学異性体の分離方法 |
DE69110528T2 (de) * | 1990-04-20 | 1996-03-14 | Inst Of Organic Chemistry And | Chirale 2-(Phosphonomethoxy)propyl-Guanine als antivirale Agentien. |
US5302585A (en) | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
SK280313B6 (sk) | 1990-04-24 | 1999-11-08 | �Stav Organick� Chemie A Biochemie Av �R | N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov |
US5627165A (en) * | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
US5177064A (en) * | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
CS276072B6 (en) | 1990-08-06 | 1992-03-18 | Ustav Organicke Chemie A Bioch | (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF |
KR100221981B1 (ko) | 1990-08-10 | 1999-09-15 | 안토닌 포레이트 | 뉴클레오티드의 신규 제조방법 |
ATE167679T1 (de) * | 1990-09-14 | 1998-07-15 | Acad Of Science Czech Republic | Wirkstoffvorläufer von phosphonaten |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US5208221A (en) | 1990-11-29 | 1993-05-04 | Bristol-Myers Squibb Company | Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives |
CZ284678B6 (cs) | 1991-05-20 | 1999-01-13 | Ústav Organické Chemie A Biochemie Avčr | Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití |
US5498752A (en) | 1991-08-22 | 1996-03-12 | Daicel Chemical Industries, Ltd. | Process for recovering optical isomers and solvent, process for using solvent by circulation and process for reusing optical isomers in optical resolution |
JP3010816B2 (ja) | 1991-08-22 | 2000-02-21 | ダイセル化学工業株式会社 | 光学分割における光学異性体と溶媒との回収方法、溶媒の循環使用方法、および光学異性体の再利用方法 |
CA2120743C (en) | 1991-10-11 | 2005-03-08 | John C. Martin | Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives |
US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
IL106998A0 (en) * | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
US6413949B1 (en) * | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
JPH09506333A (ja) * | 1993-09-17 | 1997-06-24 | ギリアード サイエンシーズ,インコーポレイテッド | 治療化合物の投薬方法 |
US5798340A (en) * | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
US5656745A (en) * | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
BR9407510A (pt) | 1993-09-17 | 1997-01-07 | Gilead Sciences Inc | Análogos de nucleotideo |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
PT828749E (pt) * | 1995-05-26 | 2003-11-28 | Genta Inc | Composicoes e metodos para a sintese de derivados de organofosforo |
CA2239020A1 (en) | 1995-12-29 | 1997-07-10 | Norbert W. Bischofberger | Nucleotide analogs |
US5717095A (en) * | 1995-12-29 | 1998-02-10 | Gilead Sciences, Inc. | Nucleotide analogs |
US5874577A (en) * | 1996-04-03 | 1999-02-23 | Medichem Research, Inc. | Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof |
JP4033494B2 (ja) * | 1996-07-26 | 2008-01-16 | ギリヤド サイエンシーズ, インコーポレイテッド | ヌクレオチドアナログ |
US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5739314A (en) | 1997-04-25 | 1998-04-14 | Hybridon, Inc. | Method for synthesizing 2'-O-substituted pyrimidine nucleosides |
TR200000224T2 (tr) | 1997-07-25 | 2000-07-21 | Gilead Sciences, Inc. | Nükleotid analog kompozisyonlar. |
SG106657A1 (en) | 1997-07-25 | 2004-10-29 | Gilead Sciences Inc | Nycleotide analog composition and sythesis method |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
WO1999030727A1 (en) * | 1997-12-17 | 1999-06-24 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
PT1045897E (pt) | 1998-01-23 | 2002-07-31 | Newbiotics Inc | Agentes terapeuticos por catalise enzimatica |
US6169078B1 (en) * | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
US6348185B1 (en) * | 1998-06-20 | 2002-02-19 | Washington University School Of Medicine | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
US6169879B1 (en) * | 1998-09-16 | 2001-01-02 | Webtv Networks, Inc. | System and method of interconnecting and using components of home entertainment system |
GB9821058D0 (en) † | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
TWI230618B (en) * | 1998-12-15 | 2005-04-11 | Gilead Sciences Inc | Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same |
ES2200820T3 (es) † | 1999-02-12 | 2004-03-16 | Glaxo Group Limited | Fosforamidato, y mono-, di- y tri-esteres fosfato de (1r,cis)-4-(6-amino-9h-purin-9-il)-2-ciclopenten-1-metanol en calidad de agentes antivirales. |
PT1301519E (pt) * | 2000-07-21 | 2015-06-11 | Gilead Sciences Inc | Profármacos de análogos de nucleótidos de fosfonato e métodos para selecionar e preparar os mesmos |
EP1345956A2 (en) * | 2000-10-13 | 2003-09-24 | University of Lausanne | Intracellular delivery of biological effectors by novel transporter peptide sequences |
US20020119433A1 (en) * | 2000-12-15 | 2002-08-29 | Callender Thomas J. | Process and system for creating and administering interview or test |
-
2001
- 2001-07-20 PT PT1961695T patent/PT1301519E/pt unknown
- 2001-07-20 SI SI200131061T patent/SI2682397T1/sl unknown
- 2001-07-20 LT LTEP13164300.9T patent/LT2682397T/lt unknown
- 2001-07-20 KR KR1020037000872A patent/KR100767432B1/ko active Protection Beyond IP Right Term
- 2001-07-20 JP JP2002514146A patent/JP4651264B2/ja not_active Expired - Lifetime
- 2001-07-20 US US10/333,107 patent/US20040018150A1/en not_active Abandoned
- 2001-07-20 EE EEP200300029A patent/EE05366B1/xx active Protection Beyond IP Right Term
- 2001-07-20 NZ NZ536942A patent/NZ536942A/xx not_active IP Right Cessation
- 2001-07-20 US US09/909,560 patent/US20020119443A1/en not_active Abandoned
- 2001-07-20 CN CNB018131611A patent/CN1291994C/zh not_active Expired - Lifetime
- 2001-07-20 ES ES01961695T patent/ES2536972T5/es not_active Expired - Lifetime
- 2001-07-20 HU HU0301307A patent/HU230960B1/hu active Protection Beyond IP Right Term
- 2001-07-20 IL IL15365801A patent/IL153658A0/xx active Protection Beyond IP Right Term
- 2001-07-20 EA EA200300188A patent/EA004926B1/ru active Protection Beyond IP Right Term
- 2001-07-20 CA CA2725819A patent/CA2725819C/en not_active Expired - Lifetime
- 2001-07-20 MX MXPA03000587A patent/MXPA03000587A/es active IP Right Grant
- 2001-07-20 CA CA2416757A patent/CA2416757C/en not_active Expired - Lifetime
- 2001-07-20 DK DK01961695.2T patent/DK1301519T4/da active
- 2001-07-20 DK DK13164300.9T patent/DK2682397T3/da active
- 2001-07-20 EP EP17160970.4A patent/EP3235823A1/en not_active Withdrawn
- 2001-07-20 EP EP01961695.2A patent/EP1301519B2/en not_active Expired - Lifetime
- 2001-07-20 BR BR0112646A patent/BRPI0112646B8/pt active IP Right Grant
- 2001-07-20 AU AU8294101A patent/AU8294101A/xx active Pending
- 2001-07-20 AP APAP/P/2003/002724A patent/AP1466A/en active
- 2001-07-20 ES ES13164300.9T patent/ES2627903T3/es not_active Expired - Lifetime
- 2001-07-20 CA CA2893174A patent/CA2893174A1/en not_active Abandoned
- 2001-07-20 AU AU2001282941A patent/AU2001282941C1/en active Active
- 2001-07-20 WO PCT/US2001/023104 patent/WO2002008241A2/en active Application Filing
- 2001-07-20 CZ CZ2013-310A patent/CZ304734B6/cs not_active IP Right Cessation
- 2001-07-20 NZ NZ535408A patent/NZ535408A/en not_active IP Right Cessation
- 2001-07-20 UA UA2003021482A patent/UA75889C2/uk unknown
- 2001-07-20 PL PL360490A patent/PL213214B1/pl unknown
- 2001-07-20 CN CNB2004100978453A patent/CN100402539C/zh not_active Expired - Lifetime
- 2001-07-20 KR KR1020067020061A patent/KR100749160B1/ko active IP Right Grant
- 2001-07-20 EP EP13164300.9A patent/EP2682397B1/en not_active Expired - Lifetime
- 2001-07-20 TR TR2003/00055T patent/TR200300055T2/xx unknown
- 2001-07-20 NZ NZ523438A patent/NZ523438A/en not_active IP Right Cessation
- 2001-07-20 HR HRP20160074AA patent/HRP20160074B1/hr not_active IP Right Cessation
- 2001-07-20 OA OA1200300003A patent/OA12393A/en unknown
- 2001-07-20 SI SI200131040T patent/SI1301519T1/sl unknown
- 2001-07-20 CZ CZ2003-413A patent/CZ304886B6/cs unknown
- 2001-07-20 PT PT131643009T patent/PT2682397T/pt unknown
-
2002
- 2002-12-19 ZA ZA2002/10271A patent/ZA200210271B/en unknown
-
2003
- 2003-01-17 IS IS6689A patent/IS2985B/is unknown
- 2003-01-20 NO NO20030270A patent/NO336718B1/no active Protection Beyond IP Right Term
- 2003-01-24 HR HRP20030047AA patent/HRP20030047B1/hr not_active IP Right Cessation
- 2003-01-28 US US10/354,207 patent/US20030219727A1/en not_active Abandoned
- 2003-02-19 BG BG107572A patent/BG66037B1/bg unknown
- 2003-08-15 HK HK03105871.0A patent/HK1054238A1/xx active IP Right Maintenance
-
2004
- 2004-02-24 US US10/785,497 patent/US20060024659A1/en not_active Abandoned
- 2004-03-11 US US10/798,692 patent/US7390791B2/en active Active
-
2005
- 2005-01-06 US US11/031,228 patent/US20050159392A1/en not_active Abandoned
- 2005-01-06 US US11/031,252 patent/US20050124585A1/en not_active Abandoned
- 2005-01-06 US US11/031,251 patent/US20050124584A1/en not_active Abandoned
- 2005-01-06 US US11/031,250 patent/US20050124583A1/en not_active Abandoned
- 2005-10-18 AU AU2005225039A patent/AU2005225039B2/en not_active Expired
-
2008
- 2008-04-28 US US12/110,829 patent/US7803788B2/en not_active Expired - Fee Related
- 2008-10-16 JP JP2008267991A patent/JP5063554B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-16 JP JP2010095542A patent/JP5111551B2/ja not_active Expired - Lifetime
-
2011
- 2011-03-08 JP JP2011050854A patent/JP2011140506A/ja not_active Withdrawn
-
2012
- 2012-04-23 NO NO20120466A patent/NO20120466L/no not_active Application Discontinuation
-
2013
- 2013-12-20 NO NO20131717A patent/NO20131717L/no unknown
-
2015
- 2015-07-10 NO NO20150909A patent/NO20150909L/no not_active Application Discontinuation
-
2016
- 2016-04-05 LT LTPA2016009C patent/LTC1301519I2/lt unknown
- 2016-04-07 BE BE2016C018C patent/BE2016C018I2/fr unknown
- 2016-04-11 FR FR16C0013C patent/FR16C0013I2/fr active Active
- 2016-04-12 CY CY2016008C patent/CY2016008I1/el unknown
- 2016-04-14 LU LU93029C patent/LU93029I2/xx unknown
- 2016-04-19 NO NO2016006C patent/NO2016006I1/no unknown
- 2016-04-22 NL NL300803C patent/NL300803I2/nl unknown
-
2017
- 2017-06-28 CY CY20171100687T patent/CY1119411T1/el unknown
-
2018
- 2018-03-09 HK HK18103347.4A patent/HK1243711A1/zh unknown
-
2019
- 2019-05-09 HU HUS1900027C patent/HUS1900027I1/hu unknown
-
2023
- 2023-02-03 NO NO2023006C patent/NO2023006I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0112646A (pt) | Pró-drogas de análogos de nucleotìdeo de fosfonato e métodos para selecionar e preparar as mesmas | |
Crumpacker | Mechanism of action of foscarnet against viral polymerases | |
HUP0402270A2 (hu) | [1,2,4]Triazolo[1,5-c]pirimidin-5-il-aminok mint adenozin A2a receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények | |
BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
BR9907270A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto | |
BR9714082A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto. | |
BR0115446A (pt) | Processos para tratamento de condições associadas a quinase p38 e compostos pirrolotriazina úteis como inibidores de quinase | |
BR0211900A (pt) | Método para inibição do desenvolvimento de vìrus e/ou virucida, análogos de nucleotìdeo de pirazina e de nucleosìdeo de pirazina, precursor do inibidor da polimerase de rna, inibidor da polimerase de rna, método para tratar pacientes infectados por vìrus, e, usos de um análogo de nucleotìdeo de pirazina ou um sal deste e de um análogo de nucleosìdeo de pirazina ou um sal deste | |
BR9907886A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd. | |
NZ522326A (en) | Adenosine A2A receptor antagonists | |
UY24560A1 (es) | Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos | |
AR026064A1 (es) | Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios. | |
CY1105866T1 (el) | Αναλογα ταμανταρινης και διδεμνινης και μεθοδοι παρασκευης και χρησης αυτων | |
BR9911488A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto | |
BRPI0409680A (pt) | análogos de fosfonato anti-cáncer | |
PA8432901A1 (es) | Compuestos de piridilpirrol | |
BR0009847A (pt) | Kit de partes, método de preparação de um kit de partes, formulação farmacêutica, método de tratamento de uma condição na qual inibição de trombina é requerida ou desejada, e, uso de um inibidor de trombina, ou de um derivado farmaceuticamente aceitável do mesmo | |
AR004480A1 (es) | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen | |
DE60036862D1 (de) | Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid-analoge | |
AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
BR0016162A (pt) | Composições e métodos para l-nucleosìdeos, lnucleotìdeos e seus análogos | |
BR0208463A (pt) | Compostos farmaceuticamente ativos | |
BR9916427A (pt) | Benzisoxazóis e fenonas como alfa2-antagonistas | |
ECSP044968A (es) | DERIVADOS DEL ÁCIDO 5,6,6a,11b-TETRAHIDRO- 7-OXA-5-AZA-BENZO [C] FLUORENO-6-CARBOXÍLICO SUSTITUIDOS COMO ANTAGONISTAS DE NMDA | |
PA8488001A1 (es) | Derivados 3-azabiciclo [3.1.0.]hexano utiles en terapia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B65X | Notification of requirement for priority examination of patent application | ||
B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07C | Technical examination (opinion): republication [chapter 7.3 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B17A | Notification of administrative nullity (patentee has 60 days time to reply to this notification) | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/07/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: "INPI NO 52402.005761/2022-42 ORIGEM: 4A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1028978-18.2022.4.01.3400 ACAO PELO PROCEDIMENTO COMUM COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: GILEAD SCIENCES, INC. E GILEAD SCIENCES FARMACEUTICA DO BRASILLTDA. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI" |
|
B19A | Notification of judicial decision: notification of judicial decision |
Free format text: PROCESSO INPI (SEI/NO) 52402.005761/2022-42 ACAO JUDICIAL 1028978-18.2022.4.01.3400 (4A VARA FEDERAL CIVEL DA SJDF (TRF1)) NUP NO 00424.147708/2022-66 AUTORAS: GILEAD SCIENCES, INC. E GILEAD SCIENCES FARMACEUTICA DO BRASIL LTDA REU INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI DECISAO: DEFIRO O PEDIDO DE TUTELA DE URGENCIA PARA DETERMINAR A (I) SUSPENSAO DO DESPACHO 16.3, PUBLICADO NA RPI NO 2629, QUE DETERMINOU A REDUCAO DO PRAZO DE VIGENCIA DA PATENTE PARA 21/07/2021 (DATA DE SUA EXPIRACAO) E, CONSEQUENTEMENTE, O REESTABELECIMENTO IMEDIATO E TEMPORARIO DA VIGENCIA DA PATENTE PI 0112646-6, ATE, PELO MENOS, ATE 17/10/2027, RESSALVADA A POSSIBILIDADE DE ENTENDIMENTO POSTERIOR |
|
B19A | Notification of judicial decision: notification of judicial decision |
Free format text: PROCESSO INPI NO 52402.005761/2022-42 SECAO JUDICIARIA DO DISTRITO FEDERAL - 4A VARA FEDERAL CIVEL DA SJDF PROCESSO: 1028978-18.2022.4.01.3400 POLO ATIVO: GILEAD SCIENCES FARMACEUTICA DO BRASIL LTDA E OUTROS POLO PASSIVO : INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI DECISAO: "ANTE O EXPOSTO: 1) DEFIRO O PEDIDO DE INGRESSO DA ABIFINA ? ASSOCIACAO BRASILEIRA DAS INDUSTRIAS DE QUIMICA FINA, BIOTECNOLOGIA E SUAS ESPECIALIDADES NA QUALIDADE DE AMICUS CURIAE. (ID. 1294987787) 2) DEFIRO O PEDIDO DE INGRESSO DO GRUPO FARMABRASIL NA QUALIDADE DE AMICUS CURIAE. (ID. 1437235771) 3) DEFIRO O PEDIDO DE TUTELA DE URGENCIA PARA DETERMINAR A (I) SUSPENSAO DO DESPACHO 16.3, PUBLICADO NA |